University of Ferrara

Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate Alzheimer’s Disease

Retrieved on: 
Tuesday, October 25, 2022

CAMBRIDGE, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized electromagnetic therapeutics to treat neurodegenerative diseases, today announced the publication of a Phase II trial conducted independently under the leadership of its co-founders, which yielded positive results demonstrating that precision-delivered noninvasive brain stimulation has the potential to slow the progression of cognitive and functional decline in patients with mild-to-moderate dementia due to Alzheimer’s disease. The findings have been published in the peer-reviewed neurology journal Brain.

Key Points: 
  • Fifty patients were enrolled in the Phase II randomized, double-blind, sham-controlled trial.
  • Treatment was well tolerated, and no serious adverse events were observed in patients treated with rTMS for 6 months.
  • These unprecedented peer-reviewed clinical results demonstrate the potential for this new class of personalized electromagnetic therapeutics to treat cognitive and functional decline safely and noninvasively in Alzheimers disease patients.
  • Sinaptica Therapeutics is a clinical-stage electromagnetic therapeutics company pioneering a personalized noninvasive brain stimulation approach with the potential to revolutionize the treatment of Alzheimers disease (AD).

Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease

Retrieved on: 
Wednesday, October 19, 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized electromagnetic therapeutics to treat neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s investigational SinaptiStim™ – AD System for the treatment of cognitive and functional decline in patients diagnosed with Alzheimer’s disease (AD). The system, a novel integration of neurostimulation and brain wave monitoring technologies in combination with a proprietary artificial intelligence (AI)-derived personalization engine, represents a new approach to treating patients suffering from dementia.

Key Points: 
  • Under the program, Sinaptica Therapeuticswill receive priority review and interactive communication with the FDA throughout the premarket review phase.
  • We are excited that the FDA has recognized the groundbreaking potential of our SinaptiStim AD System with Breakthrough Device Designation, said Rich Macary, President of Sinaptica Therapeutics.
  • Sinaptica Therapeutics is a clinical-stage electromagnetic therapeutics company pioneering a personalized noninvasive brain stimulation approach with the potential to revolutionize the treatment of Alzheimers disease (AD).
  • The company has received Breakthrough Device Designation from the U.S. Food and Drug Administration for the SinaptiStim AD System.

Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing

Retrieved on: 
Monday, September 27, 2021

On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing's for QuadraMune, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.

Key Points: 
  • On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing's for QuadraMune, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-191.
  • Following TSOI's initial research, there have been multiple studies published in peer-reviewed journals by independent academic institutions supporting the individual ingredients in QuadraMune, which are listed below by ingredients.
  • To our knowledge, QuadraMune is the only nutraceutical on the market with this level of independent scientific support for its potential use in COVID-19.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.